Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

EUMelaReg real-world outcome study: oral presentation at World Congress of Melanoma and EADO Congress in April 2025

We are delighted to inform that another EUMelaReg study was accepted for oral presentation at the 11th World Congress of Melanoma and 21st EADO Congress, which will be held on April 3-5, 2025 in Athens.

The study “Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibition in the non-resectable or metastatic setting – A EUMelaReg real world outcome study” investigates the extent to which patients with acral lentiginous melanoma (ALM) - a subtype of cutaneous melanoma (CM) that is not caused by UV radiation and shows a lower tumor mutation burden (TMB) compared to other CM - benefit from immune checkpoint inhibition therapies. While other forms of cutaneous melanoma and other skin cancers respond well to ICI due to a high, predominantly UV-induced TMB, it remains unclear whether ALM patients experience a similar benefit. The aim of the study was to investigate the response to ICI in ALM in more detail. We cordially invite you to the oral presentation of the study and look forward to the scientific exchange on site.